Recent Quotes (30 days)

You have no recent quotes
chg | %

iCo Therapeutics Inc  

(Public, CVE:ICO)   Watch this stock  
Find more results for TSE:ICO
0.0000 (0.00%)
Delayed:   10:01AM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.04 - 0.04
52 week 0.04 - 0.08
Open 0.04
Vol / Avg. 25,000.00/159,717.00
Mkt cap 2.96M
P/E     -
Div/yield     -
EPS -0.01
Shares 84.46M
Beta 0.42
Inst. own     -

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -68.29% -46.94%
Return on average equity -75.46% -48.89%
Employees 5 -
CDP Score - -


760-777 Hornby St
+1-604-6029414 (Phone)
+1-604-6029699 (Fax)

Website links


iCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.

Officers and directors

William W. Jarosz J.D. Independent Chairman of the Board
Andrew J. Rae President, Chief Executive Officer, Director
W. John Meekison Chief Financial Officer, Corporate Secretary
Peter Hnik M.D. Chief Medical Officer
Age: 51
Richard William Barker Independent Director
Age: 68
Noel F. Hall Independent Director
Age: 47
Douglas Glen Janzen Independent Director